-
2
-
-
79551563284
-
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma
-
Travis WD, Brambila E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244-285.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 244-285
-
-
Travis, W.D.1
Brambila, E.2
Noguchi, M.3
-
3
-
-
2342591455
-
The discovery of receptor tyrosine kinases: Targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370.
-
(2004)
Nat Rev Cancer
, vol.4
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
4
-
-
33847323129
-
Epidermal growth factor receptor in lung cancer
-
Sharma SV, Bell DW, Settleman J, et al. Epidermal growth factor receptor in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
-
(2007)
Nat Rev Cancer
, vol.7
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
-
5
-
-
77958478674
-
Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer
-
Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small cell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 760-774
-
-
Pao, W.1
Chmielecki, J.2
-
6
-
-
77449147803
-
Advances in target therapy for lung cancer
-
Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010; 40: 101-106.
-
(2010)
Jpn J Clin Oncol
, vol.40
, pp. 101-106
-
-
Mitsudomi, T.1
-
7
-
-
73349096261
-
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
-
Hammerman PS, Janne PA, Johnson BE. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2009; 15: 7502-7509.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 7502-7509
-
-
Hammerman, P.S.1
Janne, P.A.2
Johnson, B.E.3
-
8
-
-
24744450387
-
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer
-
Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 2005; 65: 7525-7529.
-
(2005)
Cancer Res
, vol.65
, pp. 7525-7529
-
-
Johnson, B.E.1
Janne, P.A.2
-
9
-
-
67650378948
-
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations
-
Morita S, Okamoto I, Kobayashi K, et al. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009; 15: 4493-4498.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4493-4498
-
-
Morita, S.1
Okamoto, I.2
Kobayashi, K.3
-
10
-
-
79958020132
-
EGFR-mutated lung cancer: A paradigm of molecular oncology
-
Zhang Z, Stiegler AL, Boggon TJ, et al. EGFR-mutated lung cancer: A paradigm of molecular oncology. Oncotarget 2010; 1: 497-514.
-
(2010)
Oncotarget
, vol.1
, pp. 497-514
-
-
Zhang, Z.1
Stiegler, A.L.2
Boggon, T.J.3
-
11
-
-
51049116207
-
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
-
Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008; 14: 4877-4882.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4877-4882
-
-
Wu, J.Y.1
Wu, S.G.2
Yang, C.H.3
-
12
-
-
68949201629
-
Activating and resistance mutations of EGFR in nonsmallcell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors
-
S24-S31
-
Gazdar AF. Activating and resistance mutations of EGFR in nonsmallcell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28: S24-S31.
-
(2009)
Oncogene
, vol.28
-
-
Gazdar, A.F.1
-
13
-
-
78751535304
-
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma
-
Bonanno L, Schiavon M, Nardo G, et al. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res 2010; 30: 5121-5128.
-
(2010)
Anticancer Res
, vol.30
, pp. 5121-5128
-
-
Bonanno, L.1
Schiavon, M.2
Nardo, G.3
-
14
-
-
15744372810
-
KRAS Mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
-
e17
-
Pao W, Wang TY, Riely GJ, et al. KRAS Mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
-
(2005)
PLoS Med
, vol.2
-
-
Pao, W.1
Wang, T.Y.2
Riely, G.J.3
-
15
-
-
33745888913
-
PTEN function in normal and neoplastic growth
-
Chow LML, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett 2006; 241: 184-196.
-
(2006)
Cancer Lett
, vol.241
, pp. 184-196
-
-
Chow, L.M.L.1
Baker, S.J.2
-
16
-
-
78449283888
-
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptor-activating mutations
-
Yamamoto C, Basaki Y, Kawahara A, et al. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinibresistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 8715-8725.
-
(2010)
Cancer Res
, vol.70
, pp. 8715-8725
-
-
Yamamoto, C.1
Basaki, Y.2
Kawahara, A.3
-
17
-
-
44849093355
-
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors
-
Wu Z, Gioeli D, Conaway M, et al. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. The Prostate 2008; 68: 935-944.
-
(2008)
The Prostate
, vol.68
, pp. 935-944
-
-
Wu, Z.1
Gioeli, D.2
Conaway, M.3
-
18
-
-
33846252977
-
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients
-
Endoh H, Yatabe Y, Kosaka T, et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006; 1: 629-634.
-
(2006)
J Thorac Oncol
, vol.1
, pp. 629-634
-
-
Endoh, H.1
Yatabe, Y.2
Kosaka, T.3
-
19
-
-
74949110711
-
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
-
Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Clin Oncol 2009; 28: 357-360.
-
(2009)
J Clin Oncol
, vol.28
, pp. 357-360
-
-
Jackman, D.1
Pao, W.2
Riely, G.J.3
-
20
-
-
40049099220
-
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
-
Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008; 105: 2070-2075.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, pp. 2070-2075
-
-
Yun, C.H.1
Mengwasser, K.E.2
Toms, A.V.3
-
21
-
-
33748074447
-
Presence of epidermal growth factor receptor gene T790M
-
Inukai M, Toyooka S, Ito S, et al. Presence of epidermal growth factor receptor gene T790M. Cancer Res 2006; 66: 7854-7858.
-
(2006)
Cancer Res
, vol.66
, pp. 7854-7858
-
-
Inukai, M.1
Toyooka, S.2
Ito, S.3
-
22
-
-
60549110433
-
MET increased gene copy number and primary resistance to gefitinib therapy in nonsmall-cell lung cancer patients
-
Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in nonsmall- cell lung cancer patients. Ann Oncol 2009; 20: 298-304.
-
(2009)
Ann Oncol
, vol.20
, pp. 298-304
-
-
Cappuzzo, F.1
Jänne, P.A.2
Skokan, M.3
-
23
-
-
73649102105
-
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
-
Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
-
(2010)
Cancer Cell
, vol.17
, pp. 77-88
-
-
Turke, A.B.1
Zejnullahu, K.2
Wu, Y.L.3
-
24
-
-
14844366111
-
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
-
Engelman JA, Ja'nne PA, Mermel C, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Proc Natl Acad Sci U S A 2005; 102: 3788-3793.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 3788-3793
-
-
Engelman, J.A.1
Ja'nne, P.A.2
Mermel, C.3
-
25
-
-
38049150665
-
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
-
Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104: 20932-20937.
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 20932-20937
-
-
Bean, J.1
Brennan, C.2
Shih, J.Y.3
-
26
-
-
62449250134
-
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
-
Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009; 124: 1778-1784.
-
(2009)
Int J Cancer
, vol.124
, pp. 1778-1784
-
-
Kubo, T.1
Yamamoto, H.2
Lockwood, W.W.3
-
27
-
-
33645958870
-
Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer
-
Bessho Y, Oguri T, Achiwa H, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 2006; 97: 192-198.
-
(2006)
Cancer Sci
, vol.97
, pp. 192-198
-
-
Bessho, Y.1
Oguri, T.2
Achiwa, H.3
-
28
-
-
64949108700
-
Pharmacological interplay between breast cancer resistance protein and gefitinib in epiderimal growth factor receptor signaling
-
Katayama K, Shibata K, Mitsuhashi J, et al. Pharmacological interplay between breast cancer resistance protein and gefitinib in epiderimal growth factor receptor signaling. Anticancer Res 2009; 29: 1059-1065.
-
(2009)
Anticancer Res
, vol.29
, pp. 1059-1065
-
-
Katayama, K.1
Shibata, K.2
Mitsuhashi, J.3
-
29
-
-
2442638937
-
High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter
-
Ozvegy-Laczka C, Hegedus T, Varady G, et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495.
-
(2004)
Mol Pharmacol
, vol.65
, pp. 1485-1495
-
-
Ozvegy-Laczka, C.1
Hegedus, T.2
Varady, G.3
-
30
-
-
56449089812
-
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations
-
Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-9487.
-
(2008)
Cancer Res
, vol.68
, pp. 9479-9487
-
-
Yano, S.1
Wang, W.2
Li, Q.3
-
31
-
-
77958074157
-
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
-
Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther 2010; 9: 2785-2792.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2785-2792
-
-
Okamoto, W.1
Okamoto, I.2
Tanaka, K.3
-
32
-
-
66149158452
-
Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action
-
C954-C976
-
Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action. Am J Physiol Cell Physiol 2009; 296: C954-C976.
-
(2009)
Am J Physiol Cell Physiol
, vol.296
-
-
Yamada, P.M.1
Lee, K.W.2
-
33
-
-
46749156706
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins
-
Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619.
-
(2008)
J Clin Invest
, vol.118
, pp. 2609-2619
-
-
Guix, M.1
Faber, A.C.2
Wang, S.E.3
-
34
-
-
77952338791
-
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
-
Shi F, Telesco SE, Liu Y, et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 2010; 107 7692-7697.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, pp. 7692-7697
-
-
Shi, F.1
Telesco, S.E.2
Liu, Y.3
-
35
-
-
77950216941
-
An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation
-
Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand dependent activation. Cancer Res 2010; 70: 2485-2494.
-
(2010)
Cancer Res
, vol.70
, pp. 2485-2494
-
-
Schoeberl, B.1
Faber, A.C.2
Li, D.3
-
36
-
-
80052437758
-
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer
-
Oxnard GR, Arcila ME, Chmielecki J, et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011; 17: 5530-5537.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5530-5537
-
-
Oxnard, G.R.1
Arcila, M.E.2
Chmielecki, J.3
|